Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580756 | 0.83 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL4580052 | 0.83 | HSP90AB1 (0.42) | CYP11B2HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL4579911 | 0.81 | CYP11B2 (0.41) | ARCYP11B2MEN1KMT2A | |
| SCHEMBL4582471 | 0.72 | CYP11B2 (0.42) | CYP11B2MEN1KMT2AHTR2AHTR6 | |
| SCHEMBL4582599 | 0.68 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1 | |
| SCHEMBL4582440 | 0.68 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL14292092 | 0.65 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL4579792 | 0.64 | HSP90AA1 (0.39) | ARCYP11B2HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL18272613 | 0.64 | OPRM1 (0.52) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL4580562 | 0.63 | AR (0.38) | ARCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024970-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, CCNB3 | AR 1225/4885CYP11B2 710/4885MEN1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.